Skip to main content
SpringerLink
Log in

Metabolism of Fibric Acid Derivatives

  • Correspondence
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998; 34: 155–62.

    Article  PubMed  CAS  Google Scholar 

  2. Antilipemic agents. In: McEvoy GK, editors. AHFS 97 Drug Information. Bethesda (MD): Board of Directors, American Society of Health System Pharmacists, 1997: 1346.

    Google Scholar 

  3. Lozada A, Dujovne CA. Drug interactions with fibric acids. Pharmacol Ther. 1994; 63(2): 163–76.

    Article  PubMed  CAS  Google Scholar 

  4. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73: 67–74.

    Article  PubMed  CAS  Google Scholar 

  5. Feely J, O’Connor P. Effects of HMG CoA reductase inhibitors on warfarin binding. Drug Invest. 1991; 5: 315–6.

    Google Scholar 

  6. Urien S, Albengres E, Zini R, et al. Serum binding and interactions of chlorphenoxyisobutyric acid, itanoxone and fenofibric acid according to their different HSA binding sites. In: Famagalli R, Kritchevsky D, Paoletti R, editors. Drugs affecting lipid metabolism. Amsterdam: Elsevier/North Holland Biomedical Press, 1980: 201–9.

    Google Scholar 

  7. Transon C, Thierry L, Vogt N, et al. In vivo inhibition profile of cytochrome P450tb CYP2C9) by (±) fluvastatin. Clin Pharmacol Ther. 1995; 58: 412–7.

    Article  PubMed  CAS  Google Scholar 

  8. Lown KS, Mayo R, Leichtman AB, et al. Role of intestinal p-glycoprotein (mdr 1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997; 62: 248–60.

    Article  PubMed  CAS  Google Scholar 

  9. Lees RS, Lees AM. Rhabdomyolysis from the co-administration of lovastatin and the anti-fungal agent itraconazole. N Engl J Med. 1995; 333: 664.

    Article  PubMed  CAS  Google Scholar 

  10. Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996; 60: 54–61.

    Article  PubMed  CAS  Google Scholar 

  11. Mibebradil interaction with simvastatin. Http://www.posicor.com/posicor/content/prescribe.html#CONTRAINDICATIONS. [Accessed 1998 March 30].

  12. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation. 1996; 62(11): 1559–64.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The John P. Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

    J. David Spence

Authors
  1. J. David Spence
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spence, J.D. Metabolism of Fibric Acid Derivatives. Clin Pharmacokinet 34, 419–420 (1998). https://doi.org/10.2165/00003088-199834050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199834050-00006

Keywords

Search

Navigation